Hormone Refractory Castration Resistant, Androgen-Independent Prostate Cancer Global Clinical Trials Review, H1, 2016

Hormone Refractory Castration Resistant, Androgen-Independent Prostate Cancer Global Clinical Trials Review, H1, 2016


  • Products Id :- GDHC3478CTIDB
  • |
  • Pages: 1021
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials 28

Prominent Drugs 29

Latest Clinical Trials News on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 30

May 09, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting 30

Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting 30

Mar 21, 2016: Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II 31

Clinical Trial Profile Snapshots 32

Appendix 1018

Abbreviations 1018

Definitions 1018

Research Methodology 1019

Secondary Research 1019

About GlobalData 1020

Contact Us 1020

Disclaimer 1020

Source 1021

List of Figures

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

GlobalData Methodology 1019

List of Tables

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Johnson & Johnson

Sanofi

Astellas Pharma Inc.

Novartis AG

Bayer AG

Bristol-Myers Squibb Company

Takeda Pharmaceutical Company Limited

Medivation, Inc.

AstraZeneca Plc

Eli Lilly and Company

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

select a license
Single User License
USD 2500 INR 181375
Site License
USD 5000 INR 362750
Corporate User License
USD 7500 INR 544125

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com